Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 20:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma
NCT01369888 · National Cancer Institute (NCI) · PHASE1/PHASE2 · terminated · last registry update 2015-01-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Closed this protocol due to autoimmune toxicity.” | – | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DHFR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2015-09-22Results posted on the registry: UCB Pharma SA, Certolizumab Pegol + Methotrexate (NCT01519791)
- 2015-09-07Phase 3 first posted: AstraZeneca, Durvalumab +Tremelimumab + Paclitaxel + carboplatin (NCT02542293)
- 2015-07-01Phase 3 first posted: Hoffmann-La Roche, Atezolizumab + Cisplatin (NCT02486718)
- 2015-05-25Phase 3 first posted: AstraZeneca, MEDI4736 (Durvalumab) + MEDI4736 (Durvalumab)+Tremelimumab (NCT02453282)
- 2014-07-31Phase 3 first posted: North American Consortium for Histiocytosis, Prednisone + Vinblastine (NCT02205762)
- 2014-05-02Phase 3 first posted: ETOP IBCSG Partners Foundation, Denosumab (NCT02129699)
- 2014-04-14Phase 3 first posted: National Cancer Institute (NCI), Bortezomib + Cyclophosphamide (NCT02112916)
- 2014-04-02Phase 3 first posted: National Cancer Institute (NCI), Asparaginase + Blinatumomab (NCT02101853)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision